FERRARI, I.V. Antiretroviral Promise: Amentoflavone and Nilotinib Strong Binding and Low Toxicity Against HIV-1 Reverse Transcriptase. Preprints2023, 2023120806. https://doi.org/10.20944/preprints202312.0806.v1
APA Style
FERRARI, I.V. (2023). Antiretroviral Promise: Amentoflavone and Nilotinib Strong Binding and Low Toxicity Against HIV-1 Reverse Transcriptase. Preprints. https://doi.org/10.20944/preprints202312.0806.v1
Chicago/Turabian Style
FERRARI, I.V. 2023 "Antiretroviral Promise: Amentoflavone and Nilotinib Strong Binding and Low Toxicity Against HIV-1 Reverse Transcriptase" Preprints. https://doi.org/10.20944/preprints202312.0806.v1
Abstract
In this preliminary investigation, a concise molecular docking study using the Pyrx program screened thousands of compounds against the active site of HIV-1 reverse transcriptase. The Virtual Screening library was employed to assess binding energetics scores, focusing on identifying candidates with high Vina Scores. Eight compounds, including Tetrophan, Imatinib, Amentoflavone, Alprazolam, Bilobetin, Bafetinib, Nilotinib, and Ginketin, emerged as promising candidates with significant binding energies.Recognizing compounds that strongly bind to HIV-1 reverse transcriptase holds potential for antiretroviral drug development in the fight against HIV infection. Subsequently, the study evaluated the toxicity properties of these candidates using pKCSM. Amentoflavone, a natural biflavonoid found in Ginkgo biloba and Nilotinib, a tyrosine kinase inhibitor, demonstrated lower overall toxicity profiles compared to other candidates. Further toxicity analysis using Pro-Tox-II revealed Amentoflavone's higher predictive LD50, lower toxicity class, and reduced probabilities of hepatotoxicity, carcinogenicity, mutagenicity, and moderate immunotoxicity compared to Nilotinib. While Nilotinib, a pharmaceutical drug, exhibited higher probabilities of adverse effects in these categories. In summary, Amentoflavone and Nilotinib present as promising candidates with lower toxicity concerns. Amentoflavone, as a natural substance, showcases a more favorable toxicity profile than Nilotinib, offering valuable insights for potential therapeutic applications.
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
